Tyramine and benzylamine partially but selectively mimic insulin action on adipose differentiation in 3T3-L1 cells.
Biogenic amines like tyramine, methylamine and the non-naturally occuring amine, benzylamine, have been described to promote adipose conversion of murine 3T3 preadipocytes. To further investigate these novel effects of amines, we studied whether they selectively mimic the long-term adipogenic action of insulin. To this aim, we decided to use the 3T3-L1 cell line since this model needs a complex combination of inducers to trigger the differentiation programme: insulin, isobutylmethylxanthine (IBMX, an activator of cAMP-signal transduction pathway) and the synthetic glucocorticoid, dexamethasone. A cell culture protocol was designed, by which each component of the differentiation cocktail was replaced with either benzylamine or tyramine, in order to determine whether these amine oxidase substrates could substitute any of the differentiation inducers in 3T3-L1 cells. The incomplete lipid accumulation found in cells grown under IBMX- or dexamethasone-free conditions was not improved by the daily addition of amines to the culture medium. Insulin was the only component of adipose differentiation cocktail of 3T3-L1 that could be replaced, although partially, by tyramine or benzylamine. When used at 0.5 mM, these amines resulted in a significant increase of triacylglycerol accumulated eight days after confluence, when compared to cells kept without insulin. This partial insulin replacement was totally abolished by SSAO-inhibitors, while MAO-blockade did not reduce lipid accumulation. As previously reported for other insulin-sensitive processes, such as stimulation of glucose transport or lipolysis inhibition in mature adipocytes, the stimulation of adipogenesis by tyramine and benzylamine was an SSAO-dependent mechanism that apparently shared common signaling pathways with insulin.
Institut National de la Santé et de la Recherche Médicale, U586, CHU Rangueil, 31043 Toulouse, France.
C
C
Subra
E
E
Fontana
V
V
Visentin
X
X
Testar
C
C
Carpéné
D015056:1-Methyl-3-isobutylxanthine / Q000378:metabolism / Q000494:pharmacology; D016475:3T3 Cells; D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D000273:Adipose Tissue / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D001596:Benzylamines / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D040761:Biomimetic Materials / Q000378:metabolism / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D003907:Dexamethasone / Q000378:metabolism / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism / Q000494:pharmacology*; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000494:pharmacology; D014280:Triglycerides / Q000737:chemistry / Q000378:metabolism; D014439:Tyramine / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*
D001596:Benzylamines; D007328:Insulin; D008996:Monoamine Oxidase Inhibitors; D014280:Triglycerides; D003907:Dexamethasone; C030796:benzylamine; D006631:Amine Oxidase (Copper-Containing); D015056:1-Methyl-3-isobutylxanthine; D014439:Tyramine